Aisunbeth: "It is the function of the weakness in the biotech market."
Aisunbeth/others: I believe that "Aisunbeth" is partly correct. However, perhaps (IMO) the more likely "bigger" issue is the fact that the ASX does not seem to be able to value BIOTECH stocks correctly.
Regardless: NEU is a great stock to hold or buy more of at the current share-price level. Again: IMO.
wasa
Media News, page-200
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 3429 | 4 |
View Market Depth
| Last trade - 16.16pm 08/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable